The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk non–muscle invasive bladder cancer.

Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.

Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients with breast cancer.

Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.

Ursula A. Matulonis, MD, surveyed the exploitable genetic changes driving the next wave of ovarian cancer trials, from CDK2 and WEE1 inhibitors to PARG inhibitors.

Ursula A. Matulonis, MD, broke down the trial design, backbone regimen, and preclinical rationale that she believes made KEYNOTE-B96 a positive study.

Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in this decision.

Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and sexual health.